Cosmetic Surgery Today

Plastic Surgery News, Costs of Cosmetic Surgery and Elective Procedures Blog

Artefill Study Shows Promising Results

Posted by Cosmetic Surgery Review on May 12, 2010

Artefill continues to be among the most sought-after injectable fillers in the United States. It is designed to fill wrinkles and lines, including naso-labial folds, and was recently featured in the Dermatologic Surgery journal, the official Journal of the American Society of Dermatologic Surgery, as an effective treatment with a high level of patient satisfaction.

The report in Dermatologic Surgery features the results of an ongoing 5-year study of safety and patient satisfaction with Artefill. It highlights the filler’s safety profile, and the level of patient satisfaction with Artefill 18 months after receiving the injectable, and throughout the five year period.

Approximately 80 percent of patients in this study were either satisfied or very satisfied with their treatment throughout the follow up period, making Artefill among the leading fillers with a very high rating and positive patient profile.

The study included 1,008 patients who had no recent history of fillers, and the fillers only administered to the nasolabial folds. Each patient received between two and three injections of Artefill, over a 30-day and 60-day period until full correction was received. Each patient filled out a questionnaire detailing any adverse side effects and their level of satisfaction at every six months up to 60 months after their treatment.

According to the study’s results, only 6% of patients experienced any adverse side effects, and only one out of the 1,008 patients was affected by granuloma, a condition where a mass of immune cells forms in an area after tissue injury.  Even this condition resolved itself quickly with medical treatment.

Dr. Steven Cohen, a clinical professor at the University of California, San Diego, and co-author of the study states, “Our findings further substantiate the safety of this PMMA microsphere dermal filler and we hope will alleviate some of the misperceptions in the market about its long-term safety profile.”


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: